MedPath

HK inno.N Corporation

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

90

Active:1
Completed:62

Trial Phases

4 Phases

Phase 1:61
Phase 2:4
Phase 3:16
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (89 trials with phase data)• Click on a phase to view related trials

Phase 1
61 (68.5%)
Phase 3
16 (18.0%)
Phase 4
8 (9.0%)
Phase 2
4 (4.5%)

This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants

Phase 1
Not yet recruiting
Conditions
Chronic Idiopathic Constipation
Interventions
Drug: IN-114199 10mg or placebo
Drug: IN-114199 20mg or placebo
Drug: IN-114199 2.5mg or placebo
Drug: IN-114199 5mg or placebo
Drug: IN-114199 40mg or placebo
First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
80
Registration Number
NCT06736912
Locations
🇰🇷

Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers

Phase 1
Active, not recruiting
Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
Drug: IN-G00002
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
60
Registration Number
NCT06725355
Locations
🇰🇷

Central Hospital, Clinical Trial Center, Siheung, Korea, Republic of

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Recruiting
Conditions
Adjuvant Chemotherapy
First Posted Date
2024-04-29
Last Posted Date
2024-04-29
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
36
Registration Number
NCT06389552
Locations
🇰🇷

Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

First Posted Date
2024-03-27
Last Posted Date
2024-03-27
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
36
Registration Number
NCT06332638
Locations
🇰🇷

Inje University Busan Paik Hospital, Busan, Korea, Republic of

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Phase 1
Not yet recruiting
Conditions
Healthy
Interventions
First Posted Date
2023-12-11
Last Posted Date
2023-12-11
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
48
Registration Number
NCT06164834
Locations
🇰🇷

Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 18
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath